Elimination of ketoprofen from the stratum corneum after topical administration with ketoprofen formulations in human subjects. 2014

Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
Medical Corporation Shinanokai Shinanozaka Clinic, 20 Samon-cho, Shinjuku-ku, Tokyo 160-0017, Japan. Electronic address: m-takeshi@shinanokai.com.

OBJECTIVE To assess the drug concentrations and elimination rate of ketoprofen in the stratum corneum following topical administration of two different formulations in human subjects for reference in the risk management of photocontact dermatitis caused by topical ketoprofen. METHODS Ketoprofen tape and gel were used as test formulations. The stratum corneum at the application sites was removed by tape-stripping at scheduled times after removal of the formulations. The ketoprofen concentration in the stratum corneum was determined by liquid chromatography with tandem mass spectrometry. RESULTS The ketoprofen concentration in the stratum corneum decreased and the elimination half-life in the stratum corneum was comparable between tape and gel after removal of the test formulations. The ketoprofen concentration in the stratum corneum decreased more rapidly after the subjects took a shower. Ketoprofen was not detected in the stratum corneum adjacent to the tape application sites. CONCLUSIONS Ketoprofen in the stratum corneum appears to reach the lower limit of quantitation (0.005 μg) 12-16 days after removal of tape or gel. This period is similar to that recommended for avoiding ultraviolet light after removal of topical ketoprofen formulations in the Summary of Product Characteristics for topical ketoprofen in the European Union.

UI MeSH Term Description Entries
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D007660 Ketoprofen An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. Benzoylhydratropic Acid,19,583 RP,2-(3-Benzoylphenyl)propionic Acid,Alrheumat,Alrheumum,Orudis,Profenid,RP-19583,RP 19583,RP, 19,583,RP19583
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D004350 Drug Residues Drugs and their metabolites which are found in the edible tissues and milk of animals after their medication with specific drugs. This term can also apply to drugs found in adipose tissue of humans after drug treatment. Drug Residue,Residue, Drug,Residues, Drug
D004817 Epidermis The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
April 2012, Journal of veterinary pharmacology and therapeutics,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
August 2015, Cutis,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
November 2003, Pharmaceutical research,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
October 1999, International journal of pharmaceutics,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
December 2016, European journal of drug metabolism and pharmacokinetics,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
January 2002, Cellular & molecular biology letters,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
January 2002, Cellular & molecular biology letters,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
May 2007, Contact dermatitis,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
September 1972, Archives of dermatology,
Masahiko Takeshi, and Tamotsu Ebihara, and Kotaro Maekawa, and Kaori Yamamoto, and Naruhito Higo
January 2001, Skin pharmacology and applied skin physiology,
Copied contents to your clipboard!